Discovery of a Potent, Selective and In Vivo Active Aurora A PROTAC Degrader from a Promiscuous Kinase Inhibitor
Journal of Medicinal Chemistry · 11.06.2026 · 69 (11) · 13207-13221
DOI: 10.1021/acs.jmedchem.6c00183 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 29.05.2026. Verfasst von Yulin Mao und 10 weiteren Autor:innen. Beteiligte Einrichtung: International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MO…. Hauptthemen laut MEDLINE: Aurora Kinase A, Drug Discovery, Protein Kinase Inhibitors, Proteolysis Targeting Chimera. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Chinese Academy of Sciences, State Key Laboratory of Chemical Biology.
Abstract (Originalsprache)
Discovering novel kinase modulators that combine high selectivity with the ability to regulate noncatalytic functions remains a crucial goal in kinase drug discovery. Here, we use Aurora A as a case study to demonstrate that proteolysis-targeting chimeras (PROTACs) provide a compelling solution to these challenges. We discovered M9101, a potent, selective and in vivo active Aurora A PROTAC degrader, developed from a promiscuous kinase inhibitor warhead. M9101 potently degrades Aurora A with a DC50 value of 2.3 nM in MD-MBA-231 cells and demonstrates exceptional selectivity in a global proteomic analysis. Furthermore, M9101 effectively depletes Aurora A in vivo. This study presents a valuable chemical tool for probing the noncatalytic biology of the kinase and, importantly, highlights that selective kinase degraders are achievable even from promiscuous binding ligands.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Developme…
- State Key Laboratory of Chemical Biology and Shanghai Hongkong Joint Laboratory in Chemical Synthesis, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, #345 Lingling Road, Shanghai 200032, China.
- Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China.
ORCID-Profile: Fengtao Zhou, Weixue Huang, Ke Ding, Zhen Wang
Förderung
- National Key Research and Development Program of China
- Chinese Academy of Sciences
- State Key Laboratory of Chemical Biology
Zitieren
APA
Mao, Y., Zhang, M., Tang, H., Li, J., Wang, J., Zhou, F., Zhang, J., Huang, W., Ren, X., Ding, K., & Wang, Z. (2026). Discovery of a Potent, Selective and In Vivo Active Aurora A PROTAC Degrader from a Promiscuous Kinase Inhibitor. Journal of Medicinal Chemistry, 69(11), 13207-13221. https://doi.org/10.1021/acs.jmedchem.6c00183
Vancouver
Mao Y, Zhang M, Tang H, Li J, Wang J, Zhou F, et al. Discovery of a Potent, Selective and In Vivo Active Aurora A PROTAC Degrader from a Promiscuous Kinase Inhibitor. Journal of Medicinal Chemistry. 2026;69(11):13207-13221. doi:10.1021/acs.jmedchem.6c00183
BibTeX
@article{Mao2026,
author = {Mao, Yulin and Zhang, Meiying and Tang, Hao and Li, Jiaguo and Wang, Jie and Zhou, Fengtao and Zhang, Jinwei and Huang, Weixue and Ren, Xiaomei and Ding, Ke and Wang, Zhen},
title = {Discovery of a Potent, Selective and In Vivo Active Aurora A PROTAC Degrader from a Promiscuous Kinase Inhibitor},
journal = {Journal of Medicinal Chemistry},
year = {2026},
volume = {69},
number = {11},
pages = {13207--13221},
doi = {10.1021/acs.jmedchem.6c00183}
}
EUVIMED